Mustang Bio focuses on CD20 antigen for CAR T-cell therapy

May 27, 2022 -- Chimeric antigen receptor (CAR) T cells that target the CD19 antigen have made the jump from the laboratory to the clinic with remarkable results, but biopharmaceutical company Mustang Bio is focused on a CD20-targeted autologous CAR T-cell therapy for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and Waldenstrom macroglobulinemia.

Dr. Bruce Dezube, senior vice president and head of clinical development at Mustang Bio, spoke to at the American Society of Gene & Cell Therapy (ASGCT) 2022 annual meeting in Washington, DC, about the targeting of the CD20 antigen.

"CAR T cells have revolutionized the life of the relapsed/refractory lymphoma patients; 50% of them do survive," said Dezube, who has been an oncologist for 36 years. "For the 50% who don't survive, that's a problem. And, so, the way we are personally addressing it is we're going after a different target."

While CD19 and B-cell maturation antigen are the only antigens for which there are U.S. Food and Drug Administration-approved CAR T-cell therapies, Dezube called CD20 a "very well validated antigen in the lymphoma field" and noted that "it is not lost," whereas patients treated with CD19 CAR T therapy "approximately a third of them will lose their antigen over time."

Listen to the audio recording below to learn more.

Copyright © 2022

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.